Publicaciones en colaboración con investigadores/as de Institut d'Investigacions Biomèdiques August Pi i Sunyer (25)

2022

  1. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1736-1750

  2. SARS-CoV-2 vaccine excipients polyethylene glycol and trometamol do not induce mast cell degranulation, in an in vitro model for non-IgE-mediated hypersensitivity

    Frontiers in Allergy, Vol. 3

2021

  1. Author Correction: MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia (Scientific Reports, (2018), 8, 1, (11628), 10.1038/s41598-018-29965-8)

    Scientific Reports

  2. Erratum: MYO1F Regulates IgE and MRGPRX2-Dependent Mast Cell Exocytosis (Journal of Immunology (2021) 206 (2277-2289) DOI: 10.4049/jimmunol.2001211)

    Journal of Immunology

  3. MYO1F regulates IgE and MRGPRX2-dependent mast cell exocytosis

    Journal of Immunology, Vol. 206, Núm. 10, pp. 2277-2289

  4. The multifaceted mas‐related g protein‐coupled receptor member x2 in allergic diseases and beyond

    International Journal of Molecular Sciences, Vol. 22, Núm. 9

2019

  1. Psychometric properties of the Spanish version of the once-daily Urticaria Activity Score (UAS) in patients with chronic spontaneous urticaria managed in clinical practice (the EVALUAS study)

    Health and Quality of Life Outcomes, Vol. 17, Núm. 1

  2. Therapeutic strategy according to differences in response to omalizumab in patients with chronic spontaneous urticaria giménez

    Journal of Investigational Allergology and Clinical Immunology, Vol. 29, Núm. 5, pp. 338-348

2018

  1. MRGPRX2-mediated mast cell response to drugs used in perioperative procedures and anaesthesia

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Allergic rhinitis severity can be assessed using a visual analogue scale in mild, moderate and severe

    Rhinology, Vol. 55, Núm. 1, pp. 34-38

  2. Mechanisms, cofactors, and augmenting factors involved in anaphylaxis

    Frontiers in Immunology

  3. Omalizumab efficacy in cases of chronic spontaneous urticaria is not explained by the inhibition of sera activity in effector cells

    Scientific Reports, Vol. 7, Núm. 1

2016

  1. Comparable actions of omalizumab on mast cells and basophils

    Clinical and Experimental Allergy, Vol. 46, Núm. 1, pp. 92-102

2015

  1. Management of urticaria: Not too complicated, not too simple

    Clinical and Experimental Allergy, Vol. 45, Núm. 4, pp. 731-743

2013

  1. Analysis of comorbidities and therapeutic approach for allergic rhinitis in a pediatric population in Spain

    Pediatric Allergy and Immunology, Vol. 24, Núm. 7, pp. 678-684

  2. ESPRINT-15 questionnaire (Spanish version): Reference values according to disease severity using both the original and the modified ARIA classifications

    Journal of Investigational Allergology and Clinical Immunology, Vol. 23, Núm. 1, pp. 14-19

2012

  1. Validation of the modified allergic rhinitis and its impact on asthma (ARIA) severity classification in allergic rhinitis children: The PEDRIAL study

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 67, Núm. 11, pp. 1437-1442

2011

  1. Validation of ARIA (Allergic Rhinitis and its Impact on Asthma) classification in a pediatric population: The PEDRIAL study

    Pediatric Allergy and Immunology, Vol. 22, Núm. 4, pp. 388-392

2010

  1. Validation of ARIA duration and severity classifications in Spanish allergic rhinitis patients - The ADRIAL cohort Study

    Rhinology, Vol. 48, Núm. 2, pp. 201-205

2009

  1. Allergic conjunctivitis and H1 antihistamines

    Journal of Investigational Allergology and Clinical Immunology, Vol. 19, Núm. SUPPL. 1, pp. 11-18